QTc Study With Flucticasone Furoate & GW642444

Conditions:   Asthma;   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination;   Drug: Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination;   Drug: Placebo Inhaler;   Drug: Moxifloxacin 400mg;   Drug: Moxifloxacin placebo
Sponsor:   GlaxoSmithKline
Recruiting – verified September 2010

View full post on ClinicalTrials.gov: “Asthma” | updated in the last 30 days

Leave a Reply

Your email address will not be published. Required fields are marked *